vTv Therapeutics (NASDAQ:VTVT) Shares Pass Below Fifty Day Moving Average of $17.45

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $17.45 and traded as low as $14.26. vTv Therapeutics shares last traded at $15.17, with a volume of 18,091 shares.

Analyst Ratings Changes

Separately, StockNews.com cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 13th.

vTv Therapeutics Stock Performance

The business’s fifty day moving average price is $17.39 and its two-hundred day moving average price is $20.16. The stock has a market capitalization of $44.58 million, a P/E ratio of -1.68 and a beta of 0.65.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.81) earnings per share for the quarter.

Institutional Trading of vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. Baker BROS. Advisors LP purchased a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned about 3.23% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.